Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, October 02, 2025
Made Scientific, a cell therapy contract development and manufacturing organization (CDMO) and Syenex, a synthetic biology company specializing in targeted delivery technologies, announced a technology partnership to advance the scalability and ...
read more
Monday, September 08, 2025
Made Scientific and Hemogenyx Pharma announced a manufacturing partnership to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia (r/r...
read more
Tuesday, November 25, 2025
Under this collaboration, Cellergy Therapeutics will leverage Made Scientific's GMP manufacturing capabilities to implement and scale Cellergy's proprietary mitochondrial isolation and purification process. The work will support the production of ...
read more
Wednesday, April 24, 2019
Macrogen announced it has signed a supply contract with Exosome Plus to become the exclusive buyer of the exosome isolation kits developed by Exosome Plus.
read more
Macrogen has received GCLP (Good Clinical Laboratory Practice) accreditation from the Ministry of Food and Drug Safety (MFDS) in Korea.
read more
Macro Trials, a precision research clinical platform, launched today to transform clinical trials. The company’s founders incubated Macro Trials with INITIATE Studios, a venture studio that co-creates companies at the intersection of healthcare, life...
read more
Monday, February 05, 2024
mAbxience announced an agreement with Biosidus in which mAbxience will be responsible for the manufacture of the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme.
read more
Thursday, November 05, 2015
MabVax Therapeutics Holdings, a clinical-stage oncology drug development company, has completed manufacturing of the bulk clinical-quality drug substance of HuMab 5B1 in preparation for the planned initiation of two Phase I clinical trials with this ...
read more
MabPlex has established their new state of the art Process Development Center of Excellence located in La Jolla, CA with scale up capacity to 200L.
read more
Wednesday, August 14, 2019
M2Gen announced the appointment of Helge Bastian, Ph.D., as president and chief executive officer (CEO).
read more
Lysogene announced it has entered into a manufacturing agreement with viral gene and cell therapy manufacturer Brammer Bio.
read more
Tuesday, November 01, 2011
This advanced form of a highly purified novel vaccine, developed by a leading vaccine company in Japan promises to provide highly effective protection from a severely debilitating infection while exhibiting a superior patient safety profile.
read more
Wednesday, September 21, 2022
Lykan Bioscience named Barbara Ressler, Ph.D. VP of Manufacturing Process Sciences. development, process development and manufacturing science and technology (MS&T) teams.
read more
Lykan Bioscience, a contract development and manufacturing organization (CDMO) focused on cell-based therapies, and Vineti, the world’s only enterprise software platform supporting supply chain orchestration for clinical and commercial cell therapies...
read more
Lyell Immunopharma and PACT Pharma have announced a strategic partnership to jointly develop and test a next generation personalized anti-cancer T cell therapy against solid tumors.
read more